Comparison · NCT00612430-d158eb82
Grade III vs Grade IV: Safety of Study Treatment Regimen
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Grade III vs Grade IV: Safety of Study Treatment Regimen. Trial comparisons, record NCT00612430-d158eb82. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00612430-d158eb82
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.281 | 0.156 | 0.454 | wilson | |
| Risk in group 2 | 0.481 | 0.307 | 0.66 | wilson | |
| Risk difference, group 1 minus group 2 | -0.2 | -0.419 | 0.0448 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.584 | 0.296 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 0.421 | 0.143 | 1.24 | log | |
| Number needed to treat, for one fewer participant with the outcome on Grade III than on Grade IV | 4.99 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Grade III | 9 | 32 | OG000 | |
| Group 2 | Grade IV | 13 | 27 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Safety of Study Treatment Regimen
- Description
- Number of participants experiencing a non-hematologic toxicity ≥ grade 3 that was possibly, probably, or definitely related to study treatment.
- Time frame
- 2 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
- NCT number
- NCT00612430
- Phases
- PHASE2
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab and Etoposide
- Lead sponsor
- Duke University
- Results first posted
- 2013-07-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00612430?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00612430-d158eb82